Limaprost is a Small Molecule owned by Sumitomo Pharma, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.
Limaprost alfadex targets the prostaglandin E1 receptor and agonizes it. Limaprost inhibits platelet aggregation and has vasodilating effects. The drug candidate is a prostaglandin E(1) analog, has vasodilatory properties and increases blood flow of the nerve root. Prostaglandin E1 produces endogenously to relax vascular smooth muscle and cause vasodilation. The mechanism of symptoms in cervical spondylosis is that the mechanical compression of spinal cord by bony spur which is disturbed the blood flow of spinal cord and nerve roots.
The revenue for Limaprost is expected to reach a total of $115m through 2030. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Limaprost NPV Report.
Limaprost was originated by Ono Pharmaceutical and Sumitomo Pharma and is currently owned by Sumitomo Pharma. Ono Pharmaceutical is the other company associated in development or marketing of Limaprost.
Limaprost alfadex (Prorenal, Opalmon) is an oral prostaglandin E1 derivative formulation which is formulated as tablets for oral administration. It is indicated for the treatment of ischemic symptoms such as ulcer, pain, coldness due to obstructive thrombosis vasculitis, lumbar spinal stenosis symptoms due to aids.
Ono Pharmaceutical Overview
Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.
Quick View – Limaprost
|Highest Development Stage|